TD Cowen Upgrades CVS Health to Buy, Raises Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
TD Cowen has upgraded CVS Health from Hold to Buy, raising the price target from $59 to $85, indicating a positive outlook for the company's stock.
October 04, 2024 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen has upgraded CVS Health from Hold to Buy, with a new price target of $85, suggesting a positive short-term outlook for the stock.
The upgrade from Hold to Buy by TD Cowen, along with a significant increase in the price target from $59 to $85, indicates a strong positive sentiment from the analyst. This is likely to boost investor confidence and could lead to an increase in CVS's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100